Humana AB (LTS:0RF7) ROCE %: 5.65% (As of Mar. 2026)

What is Humana AB ROCE %?

Humana AB LTS:0RF7 +3.44% 67 ROCE % is 5.65% as of Mar. 2026. GuruFocus rates LTS:0RF7 with a GF Score™ of 67/100 and a GF Value™ of kr36.46 (Significantly Overvalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Humana AB's annualized ROCE % for the quarter that ended in Mar. 2026 was 5.65%.

Humana AB (LTS:0RF7) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Humana AB ROCE % Related Terms

Humana AB ROCE % Historical Data

* Premium members only.

The historical data trend for Humana AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Humana AB ROCE % Chart

Humana AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

7.45

5.82

6.20

6.17

6.91

Humana AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															7.66	3.97	11.18	4.69	5.65

67GF Score

Humana AB LTS:0RF7

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Humana AB ROCE % Calculation

Humana AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	520	/	( ( (10626 - 2735)	+	(9394 - 2236) )	/ 2 )
	=	520	/	( (7891	+	7158)	/ 2 )
	=	520	/	7524.5
	=	6.91 %

Humana AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	404	/	( ( (9394 - 2236)	+	(9465 - 2327) )	/ 2 )
	=	404	/	( ( 7158	+	7138 )	/ 2 )
	=	404	/	7148
	=	5.65 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 5.65% mean?

Humana AB (LTS:0RF7) has a ROCE % of 5.65% as of Mar. 2026.

Is Humana AB's ROCE % too high?

Humana AB's current ROCE % is 5.65%. The Healthcare Providers & Services industry median ROCE % is 6.41. Humana AB's value of 5.65% is 11.9% below this industry median. Overall, Humana AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Humana AB's ROCE % compare to HCA and THC?

Humana AB's ROCE % of 5.65% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. Humana AB's value of 5.65% is 11.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Healthcare Providers & Services company?

The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Humana AB's current ROCE % of 5.65% is 11.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Humana AB's current ROCE % is 5.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Humana AB stock overvalued right now?

Based on GuruFocus' analysis, Humana AB (LTS:0RF7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr36.46, compared to a current price of kr48.13 — trading 32% above its estimated fair value. The current ROCE % is 5.65% and 11.9% below the Healthcare Providers & Services industry median of 6.41. Humana AB's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Humana AB (LTS:0RF7), the current ROCE % is 5.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Humana AB (LTS:0RF7) Overvalued in 2026?

Based on GuruFocus' analysis, Humana AB stock appears to be overvalued. The current stock price of kr48.13 is trading 32% above its estimated GF Value™ of kr36.46. GuruFocus considers Humana AB to be Significantly Overvalued.

Key valuation signals for LTS:0RF7:

ROCE %: 5.65%
GF Value™: kr36.46 vs. price of kr48.13 (32% above fair value)
GF Score™: 67/100 with 3 warning signs
Industry Position: 11.9% below the Healthcare Providers & Services median

No single metric tells the full story. See the LTS:0RF7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Humana AB Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies OSTO:AMBEA HCA XTER:FRE SAU:4013 XKLS:5225 THC BSP:RDOR3 SZSE:300015 DVA NSE:APOLLOHOSP XTER:FME EHC BOM:543220 ENSG ISX:SRAJ BKK:BDMS UHS BOM:532843 ADX:PUREHEALTH ASX:RHC

Other Exchanges HUM:Sweden HUMs:UK

Address Warfvinges vag 39, 7th Floor, Stockholm, SWE, SE-112 51

Website https://www.humana.se

Humana AB is a provider of private care services in the Nordic region. The company offers services including individual and family care, personal assistance, elderly care and housing with special services. Geographically, the company operates in Sweden, Norway, Finland, Denmark, and others. It derives maximum revenue from Sweden.

67GF Score

Get the complete analysis for LTS:0RF7

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr48.13

Price

kr36.46

GF Value

View LTS:0RF7 Analysis

See ROCE % data for all stocks →